RESEARCH MONOGRAPH · KDC-MN-022
Solriamfetol
Solriamfetol, sold as Sunosi, is a wakefulness-promoting medication FDA-approved in 2019 for daytime sleepiness in narcolepsy and obstructive sleep apnea. It is a selective dopamine and norepinephrine reuptake inhibitor with clean pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Selective dopamine and norepinephrine reuptake inhibitor
An FDA-approved (2019) phenylalanine-derived dual norepinephrine and dopamine reuptake inhibitor for excessive daytime sleepiness in narcolepsy and OSA.
Abstract
Solriamfetol (Sunosi; JZP-110, ADX-N05; CAS 178429-65-3; molecular formula C10H14N2O2; molecular weight 194.23) is a phenylalanine-derived dual norepinephrine and dopamine reuptake inhibitor approved by the FDA in March 2019 for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The compound was originated at SK Biopharmaceuticals, advanced through Phase 3 by Aerial BioPharma, and acquired by Jazz Pharmaceuticals. Mechanism is selective inhibition of the norepinephrine and dopamine transporters with negligible serotonin transporter activity; the pharmacology distinguishes solriamfetol from both modafinil (weak DAT, no NET) and methylphenidate (DAT and NET with rapid onset). The plasma half-life is 7.1 hours; oral bioavailability is high; metabolism is minimal (the compound is excreted largely unchanged in urine). The Phase 3 program (TONES studies) demonstrated dose-dependent improvement in maintenance of wakefulness test (MWT) and Epworth Sleepiness Scale (ESS) scores in both narcolepsy and OSA populations. The studied dose ranges spanned approximately 37.5 to 150 mg. Schedule IV in the United States. Adverse events are dose-related and include headache, nausea, decreased appetite, anxiety, and insomnia; cardiovascular effects (heart rate and blood pressure elevation) are observed at higher doses. Drug-drug interactions are minimal due to the absence of significant hepatic metabolism. The compound is not approved for cognitive enhancement in healthy individuals; off-label use for that purpose is documented in the research-chemical community but the cognitive enhancement evidence base in non-sleep-deprived subjects is thin.
Mechanism of action
Dual NET/DAT reuptake inhibitor with negligible SERT activity. Distinct from modafinil (weak DAT only) and amphetamines (DAT/NET with monoamine release).
Reported research dose ranges
Clinical trials studied a range of approximately 37.5 to 150 mg.
References
- Thorpy MJ, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol 2019.
- Strollo PJ Jr, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest 2019.
- Carter LP, et al. Abuse potential of solriamfetol (JZP-110) compared with modafinil and phentermine. Neuropsychopharmacology 2018.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.